Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00471744
Status:
TERMINATED
Last Update Posted:
2009-01-29
First Post:
2007-05-08
Brief Title:
HEAD-Study Optimizing the Treatment of Children With BECTS
Sponsor:
Ludwig-Maximilians - University of Munich
Organization:
Ludwig-Maximilians - University of Munich
Study Overview
Official Title:
HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam LEV vs Sulthiame STM in a German Multi-Centre Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes
Status:
TERMINATED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
low patient number after 2 years recruiting
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HEAD
Brief Summary:
The investigators hypothesize that Levetiracetam is as effective as Sulthiame in the treatment of children with BECTS Patients entering the HEAD-Studie are either treated with Leveitracetam or Sulthiame over a 6 months period Patients are equally randomised to one of the two treatment regimens Administration of medication as blinded capsules
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ISRCTN 97864911 | None | None | None |